__
__
__
1. Miler JJ, Fletcher K, Kabat-Zinn J, et al. Three-year follow-up and
clinical implications of a mindfulness meditation-based stress reduction intervention in
the treatment of anxiety disorders. Gen Hosp Psychiatry 1995;17:192–200.
2. Bruce M et al. Anxiogenic effects of caffeine in patients with anxiety disorders. Arch
Gen Psychiatry 1992;49:867–69.
3. Weston PG et al. Magnesium sulfate as a sedative. Am J Med Sci
1923;165:431–33.
4. Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial
of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084–86.
5. Mohler H, Polc P, Cumin R, et al. Niacinamide is a brain constituent with
benzodiazepine-like actions. Nature 1979;278:563–65.
6. Vescovi PP et al. Nicotinic acid effectiveness in the treatment of benzodiazepine
withdrawal. Curr Ther Res 1987;41:1017.
7. Piscopo G. Kava kava: Gift of the islands. Alt Med Rev 1997;2:355–81
[review].
8. Lehmann EE, Kinzler J, Friedmann J. Efficacy of a special kava extract (Piper
methysticum) in patients with states of anxiety, tension and excitedness of
non-mental origin. A double-blind placebo-controlled study of four weeks treatment. Phytomedicine
1996;3:113–19.
9. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders. A
randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry
1997;30:1–5.
10. Warnecke G. Psychosomatic dysfunctions in the female climacteric. Clinical
effectiveness and tolerance of kava extract WS 1490. Fortscher Med
1991;119–22 [in German].
11. Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava and
alprazolam. Arch Intern Med 1996;125:940–41.
12. Woelk H, Kapoula S, Lehrl S, et al. Treatment of patients suffering from
anxiety—double-blind study: Kava special extract versus benzodiazepines. Z
Allegemeinmed 1993;69:271–77 [in German].
13. Volz HP, Kieser M. Kava-kava extract WS 1490 vs. placebo in anxiety disorders—A
randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry
1997;30:1–5.
14. Witte B, Harrer G, Kaptan T, et al. Treatment of depressive symptoms with a high
concentration Hypericum preparation. A multicenter placebo-controlled double-blind study. Fortschr
Med 1995;113:404–408 [in German].
15. Baureithel KH, Buter KB, Engesser A, et al. Inhibition of benzodiazepine binding in
vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv
1997;72:153–57.
16. Viola H, de Stein ML, et al. Apigenin, a component of Matricaria recutita flowers, is
a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med
1995;61:213–16.
17. Yamada K, Miura T, Mimaki Y, Sashida Y. Effect of inhalation of chamomile oil vapour
on plasma ACTH level in ovariectomized rats under restriction stress. Biol Pharm Bull
1996;19:1244–46.
18. Brown D. Valerian root: Non-addictive alternative for insomnia and anxiety. Quart
Rev Nat Med 1994;Fall:221–24 [review].
